Anti-inflammatory effects of besifloxacin, a novel fluoroquinolone, in primary human corneal epithelial cells

Current Eye Research

Volumn 33, Issue 11-12, 2008, Pages 923-932

  Zhang, Jin Zhong ^a   Cavet, Megan E ^a   Ward, Keith W ^a  

^a BAUSCH AND LOMB   (United States)

Author keywords

Interleukin 1 ; Luminex; MAPK; NF B; Ophthalmic infection; Pro inflammatory cytokine

Indexed keywords

BESIFLOXACIN; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CORNEA EPITHELIUM; CYTOKINE RELEASE; DOSE RESPONSE; EYE INFECTION; HUMAN; HUMAN CELL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AZA COMPOUNDS; AZEPINES; BIOLOGICAL TRANSPORT; CELL NUCLEUS; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPHTHALMITIS; ENZYME ACTIVATION; EPITHELIUM, CORNEAL; FEMALE; FLUOROQUINOLONES; HUMANS; INTERLEUKIN-1BETA; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; QUINOLINES; RABBITS;

EID: 57649115466     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680802478704     Document Type: Article

References (36)

1. Wilhelmus KR. The red eye. Infectious conjunctivitis, keratitis, endophthalmitis, and periocular cellulitis. Infect Dis Clin North Am. 1988; 2(1):99-116.
2. Donahue SP, Khoury JM, Kowalski RP. Common ocular infections. A prescriber's guide. Drugs. 1996;52(4):526-540.
3. Snyder RW, Glasser DB. Antibiotic therapy for ocular infection. West J Med. 1994;161(6):579-584.
4. Zhang J, Wu XY, Yu FS. Inflammatory responses of corneal epithelial cells to Pseudomonas aeruginosa infection. Curr Eye Res. 2005;30(7):527-534.
5. Chang JH, McCluskey PJ, Wakefield D. Toll-like receptors in ocular immunity and the immunopathogenesis of inflammatory eye disease. Br J Ophthalmol. 2006;90(1):103-108.
6. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376.
7. Wilson SE, Mohan RR, Mohan RR, Ambrosio Jr R, Hong J, Lee J. The corneal wound healing response: Cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. Prog Retin Eye Res. 2001;20(5):625-637.
8. Narayanan S, Glasser A, Hu YS, McDermott AM. The effect of interleukin-1 on cytokine gene expression by human corneal epithelial cells. Exp Eye Res. 2005;80(2):175-183.
9. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry eye disease. Invest Ophthalmol Vis Sci. 2001;42(10):2283-2292.
10. Rudner XL, Kernacki KA, Barrett RP, Hazlett LD. Prolonged elevation of IL-1 in Pseudomonas aeruginosa ocular infection regulates macrophage-inflammatory protein-2 production, polymorphonuclear neutrophil persistence, and corneal perforation. J Immunol. 2000;164(12):6576-6582.
11. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: New weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133(4):463-466.
12. Ward KW, Lepage JF, Driot JY. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J Ocul Pharmacol Ther. 2007;23(3):243-256.
13. Zhang JZ, Ward KW. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of proinflammatory cytokines in human THP-1 monocytes. J Antimicrob Chemother. 2008;61(1):111-116.
14. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis. 2003;3(6):359-371.
15. Dalhoff A. Immunomodulatory activities of fluoroquinolones. Infection 2005;33(Suppl 2):55-70.
16. Shalit I, Halperin D, Haite D, Levitov A, Romano J, Osherov N, Fabian I. Anti-inflammatory effects of moxifloxacin on IL-8, IL-1β, and TNF-α secretion and NFkappaB and MAP-kinase activation in human monocytes stimulated with Aspergillus fumigatus. J Antimicrob Chemother. 2006;57(2):230-235.
17. Blau H, Klein K, Shalit I, Halperin D, Fabian I. Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-κB activation in a cystic fibrosis epithelial cell line. Am J Physiol Lung Cell Mol Physiol. 2007;292(1):L343-352.
18. Werber S, Shalit I, Fabian I, Steuer G, Weiss T, Blau H. Moxifloxacin inhibits cytokine-induced MAP kinase and NF-κB activation as well as nitric oxide synthesis in a human respiratory epithelial cell line. J Antimicrob Chemother. 2005;55(3):293-300.
19. Weiss T, Shalit I, Blau H, Werber S, Halperin D, Levitov A, Fabian I. Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: Inhibition of NF-κB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines. Antimicrob Agents Chemother. 2004;48(6):1974-1982.
20. Mino De Kaspar H, Hoepfner AS, Engelbert M, Thiel M, Ta CN, Mette M, Schulze-Schwering M, Grasbon T, Sesma-Vea B, Casas JM, et al. Antibiotic resistance pattern and visual outcome in experimentally-induced Staphylococcus epidermidis endophthalmitis in a rabbit model. Ophthalmology 2001;108(3):470-478.
21. Bronner S, Jehl F, Peter JD, Ploy MC, Renault C, Arvis P, Monteil H, Prevost G. Moxifloxacin efficacy and vitreous penetration in a rabbit model of Staphylococcus aureus endophthalmitis and effect on gene expression of leucotoxins and virulence regulator factors. Antimicrob Agents Chemother. 2003;47(5):1621-1629.
22. Giese MJ, Rayner SA, Fardin B, Sumner HL, Rozengurt N, Mondino BJ, Gordon LK. Mitigation of neutrophil infiltration in a rat model of early Staphylococcus aureus endophthalmitis. Invest Ophthalmol Vis Sci. 2003;44(7):3077-3082.
23. Engelbert M, Mino de Kaspar H, Thiel M, Grasbon T, Ta CN, Schulze-Schwering M, Klauss V, Kampik A. Intravitreal vancomycin and amikacin versus intravenous imipenem in the treatment of experimental Staphylococcus aureus endophthalmitis. Graefes Archiv fur Klinische und Experimentelle Ophthalmologie 2004;242(4):313-320.
24. de Castro LE, Sandoval HP, Bartholomew LR, Vroman DT, Solomon KD. Prevention of Staphylococcus aureus endophthalmitis with topical gatifloxacin in a rabbit prophylaxismodel. J Ocul Pharmacol Ther. 2006;22(2):132-138.
25. Kowalski RP, Romanowski EG, Mah FS, Yates KA, Gordon YJ. Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model. Am J Ophthalmol. 2004;138(1):33-37.
26. Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods. 2000;243(1-2):243-255.
27. O'Brien J, Wilson I, Orton T, Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem. 2000;267(17):5421-5426.
28. Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta-4 suppression of corneal NFκB: A potential anti-inflammatory pathway. Exp Eye Research. 2007;84(4):663-669.
29. Li X, Stark GR. NFκB-dependent signaling pathways. Exp Hematol. 2002;30(4):285-296.
30. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334(26):1717-1725.
31. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned? Annu Rev Immunol. 2001;19:163-196.
32. Kumar A, Zhang J, Yu FS. Innate immune response of corneal epithelial cells to Staphylococcus aureus infection: Role of peptidoglycan in stimulating proinflammatory cytokine secretion. Invest Ophthalmol Vis Sci. 2004;45(10):3513-3522.
33. Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: Past, present, and future perspectives. Int Journal Antimicrob Agents 2000;16(1):5-15.
34. Moshirfar M, Mirzaian G, Feiz V, Kang PC. Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery. Journal Cataract Refract Surg. 2006;32(3):515-518.
35. Jhanji V, Sharma N, Satpathy G, Titiyal J. Fourth-generation fluoroquinolone-resistant bacterial keratitis. Journal Cataract Refractive Surg. 2007;33(8):1488-1489.
36. Lee S, Park T, Lee Y. Structure-activity relationship of fluoroquinolone in Escherichia coli. Arch Pharmacol Res. 1998;21(2):106-112.